IQ4I Research & Consultancy published a new report on “Active Pharmaceutical Ingredients (API) Global Market – Forecast To 2022”

Active Pharmaceutical Ingredients/bulk drug is an active substance in drug with biological activity intended for diagnosis, treatment or prevention of disease status by altering physiological condition. API can be synthesized either chemically or biotechnological means through mammalian cell culture or fermentation process which are used for wide range of therapeutic applications. API market is highly competitive with >3,000 firms and >5,500 manufacturing plants across the world with a higher proportion of players located in emerging regions due to favourable cost conditions and man power availability, thus leading to increased export of API products from these regions to various parts of the world. Limited number of finished pharmaceutical product manufacturers has their own in-house API manufacturing units. API manufacturers in developing countries face major challenges to develop product with quality at an affordable price, due to lower price of API and huge number of producers, which creates a price sensitive market. Some manufacturers may compromise the quality of product in order to keep prices low and boost sales, while some of the manufacturers having a larger market for their products, can sell their higher volume API’s at a slightly lower price. The average capacity utilization rate for active pharmaceutical ingredients (APIs) manufacturing facilities is estimated to be in range of 50-55%.

Patent expiration of prominent drugs led to increased generic drug sales, government initiatives for biomedical research, increasing scope of HPAPI market, increasing aged population and regional penetration, local manufacturer expansion and high uptake of biologics are some of the factors that are driving the market growth. Whereas financial crisis, stringent regulatory policies, less investment in API pharmaceutical industry and fragmented market are the factors that are hindering API market growth.

The global API market is segmented based on synthesis, customer base, business type and therapeutic applications. Depending on synthesis the market is classified into synthetic chemical API, biotech API and HPAPI (Highly Potent Active Pharmaceutical Ingredient). Synthetic chemicals API accounted for largest share of XX% in 2015 and biotech API is the fastest growing segment with XX% share. Biotech API is further segmented into monoclonal antibodies, recombinant proteins, vaccines and others. HPAPI segment account for 9.7% share in the overall API market. HPAPI’s are the one is fastest growing segment as they can target cells in more precise manner and require relatively low doses. Majority of the highly potent drugs under development are mainly focused on oncology therapeutic application.

Major players in the API market include Teva Active Pharmaceutical Industries Limited (Israel), Boehringer Ingelheim GmbH (Germany), Lonza group (Switzerland), Lupin (India), Novartis (Switzerland), Aurobindo pharma (India), and Albemarle Corporation (U.S.).

IQ4I (Intelligence Quotient for Innovation) Research and Consultancy Pvt. Ltd. is a global strategy, consulting and a market research firm. Our clients include leading businesses, investment banks, researchers and government agencies.

We are a team of highly qualified consultants and market researchers, committed to help clients make strategic decisions by providing relevant and firmly reliable Intelligence support. We enable our clients to identify the market opportunities with best-in-class market intelligence reports.

IQ4I Research and Consultancy Pvt. Ltd.
No- 11, Industrial Suburb, 1st Stage, West of Chord Road,
RajajiNagar, Bangalore- 560010

This release was published on openPR.